Corautus Genetics Announces Proposed Public Offering of Common Stock
25 2월 2006 - 6:42AM
PR Newswire (US)
ATLANTA, Feb. 24 /PRNewswire-FirstCall/ -- Corautus Genetics Inc.
(NASDAQ:VEGF) announced today that it has filed a preliminary
prospectus supplement relating to an offering of 6,500,000 shares
of its common stock pursuant to a Form S-3 shelf registration
statement filed last month with the U.S. Securities and Exchange
Commission. Corautus will also grant the underwriters in the
offering an option to purchase up to 975,000 additional shares of
common stock to cover over-allotments, if any. All of the shares
are being sold by Corautus. Lazard Capital Markets LLC will act as
the lead manager and sole book- runner for the offering. Jefferies
& Company, Inc. will act as co-lead manager. A preliminary
prospectus supplement has been filed today with the U.S. Securities
and Exchange Commission. Any offer of shares of Corautus' common
stock will be made only by means of a prospectus. Copies of the
preliminary prospectus supplement relating to the offering may be
obtained by contacting Lazard Capital Markets LLC at 30 Rockefeller
Plaza New York, NY 10020 or (212) 632-6000. This communication
shall not constitute an offer to sell or the solicitation of an
offer to buy, nor shall there be any sale of these securities in
any state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. About Corautus
Genetics Inc. Corautus Genetics Inc. is a biopharmaceutical company
dedicated to the development and commercialization of innovative
gene therapy products for the treatment of cardiovascular and
peripheral vascular disease. Corautus is currently developing and
testing gene therapy product candidates using the Vascular
Endothelial Growth Factor-2 (VEGF-2) gene to promote therapeutic
angiogenesis in ischemic muscle. For more information, please visit
http://www.corautus.com/. Forward-Looking Statements This press
release may contain forward-looking statements made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Such statements are subject to certain factors, risks
and uncertainties that may cause actual results, events and
performances to differ materially from those referred to in such
statements. These risks include statements which address operating
performance, events or developments that we expect or anticipate
will occur in the future, such as projections about our ongoing
clinical trial, including its cost, projections about our future
results of operations or our financial condition, benefits of
achieving Fast Track designation, benefits from the alliance with
Boston Scientific, benefits from manufacturing agreements,
research, development and commercialization of our product
candidates, the potential of additional product candidates or
indications, sufficient and timely enrollment of suitable patients
in our clinical trial, whether early-stage clinical trial results
are any indication of results in subsequent clinical trials,
anticipated trends in our business, manufacture of sufficient and
acceptable quantities of our proposed products, approval of our
product candidates, meeting additional capital requirements, and
other risks that could cause actual results to differ materially.
These risks are discussed in Corautus Genetics Inc.'s Securities
and Exchange Commission filings, including, but not limited to, the
risk factors in Corautus' Annual Report on Form 10-K for 2004 filed
on March 22, 2005, which are incorporated by reference into this
press release. All forward-looking statements included in this
press release are based on information available to Corautus on the
date hereof, and Corautus assumes no obligation to update such
forward-looking statements. CONTACTS: Michael K. Steele Corautus
Genetics Inc. 404-526-6212 Kim Golodetz Lippert/Heilshorn &
Associates 212-838-3777 Bruce Voss Lippert/Heilshorn &
Associates 310-691-7100 First Call Analyst: FCMN Contact:
DATASOURCE: Corautus Genetics Inc. CONTACT: Michael K. Steele of
Corautus Genetics Inc., +1-404-526-6212, or ; or Kim Golodetz,
+1-212-838-3777, , or Bruce Voss, +1-310-691-7100, , both of
Lippert-Heilshorn & Associates Web site:
http://www.corautus.com/
Copyright
Corautus Genetics (NASDAQ:VEGF)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Corautus Genetics (NASDAQ:VEGF)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Corautus Genetics (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Corautus Genetics (MM) News Articles